Moreover, aromatase inhibitors may cause autoimmune-related joint pain presenting with autoimmune antibodies (ANA) and rheumatoid factor (RF), while cases of rheumatoid arthritis have been reported [27,28,29]. Here, CYP19A1 is linked to rheumatoid arthritis.